SG10201506776RA - Inhibitors of bruton's tyrosine kinase - Google Patents
Inhibitors of bruton's tyrosine kinaseInfo
- Publication number
- SG10201506776RA SG10201506776RA SG10201506776RA SG10201506776RA SG10201506776RA SG 10201506776R A SG10201506776R A SG 10201506776RA SG 10201506776R A SG10201506776R A SG 10201506776RA SG 10201506776R A SG10201506776R A SG 10201506776RA SG 10201506776R A SG10201506776R A SG 10201506776RA
- Authority
- SG
- Singapore
- Prior art keywords
- bruton
- inhibitors
- tyrosine kinase
- tyrosine
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25078709P | 2009-10-12 | 2009-10-12 | |
| US12/581,062 US7741330B1 (en) | 2009-10-12 | 2009-10-16 | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| US12/581,044 US7718662B1 (en) | 2009-10-12 | 2009-10-16 | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201506776RA true SG10201506776RA (en) | 2015-10-29 |
Family
ID=42166572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201506776RA SG10201506776RA (en) | 2009-10-12 | 2010-10-12 | Inhibitors of bruton's tyrosine kinase |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US7718662B1 (es) |
| EP (2) | EP2393816A4 (es) |
| JP (2) | JP5717109B2 (es) |
| KR (1) | KR20120097376A (es) |
| CN (1) | CN102656173B (es) |
| AU (1) | AU2010306921C1 (es) |
| BR (1) | BR112012008624A2 (es) |
| CA (1) | CA2776543A1 (es) |
| CL (1) | CL2012000917A1 (es) |
| CO (1) | CO6531429A2 (es) |
| CR (1) | CR20120244A (es) |
| EA (1) | EA021715B1 (es) |
| ES (1) | ES2590905T3 (es) |
| IL (1) | IL219076A (es) |
| IN (1) | IN2012DN03012A (es) |
| MX (1) | MX2012004258A (es) |
| NZ (1) | NZ599396A (es) |
| SG (1) | SG10201506776RA (es) |
| WO (1) | WO2011046964A2 (es) |
| ZA (1) | ZA201202552B (es) |
Families Citing this family (135)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| US20120101113A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| US20100101977A1 (en) * | 2008-06-05 | 2010-04-29 | United Comb & Novelty Corporation | Stackable Packaging For Lipped Containers |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| ES2711249T3 (es) | 2008-06-27 | 2019-04-30 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
| US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| MX2011000661A (es) * | 2008-07-16 | 2011-05-25 | Pharmacyclics Inc | Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos. |
| WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
| US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| IL300955A (en) | 2010-06-03 | 2023-04-01 | Pharmacyclics Llc | (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-H1-pyrazolo[4,3-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1- Indicated for use as a drug to treat chronic lymphocytic leukemia or small lymphocytic lymphoma |
| AU2011276955B2 (en) * | 2010-07-09 | 2014-11-06 | The Walter And Eliza Hall Institute Of Medical Research | Protein kinase inhibitors and methods of treatment |
| MY160734A (en) * | 2010-08-10 | 2017-03-15 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
| EP2635285B1 (en) | 2010-11-01 | 2017-05-03 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| NZ710636A (en) | 2010-11-01 | 2017-02-24 | Celgene Avilomics Res Inc | Heterocyclic compounds and uses thereof |
| EP2637502B1 (en) | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
| WO2012135800A1 (en) | 2011-04-01 | 2012-10-04 | University Of Utah Research Foundation | Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase |
| CN103889962B (zh) * | 2011-04-01 | 2017-05-03 | 犹他大学研究基金会 | 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物 |
| HUE048834T2 (hu) * | 2011-05-17 | 2020-08-28 | Univ California | Kináz inhibitorok |
| HUE033019T2 (en) | 2011-05-17 | 2017-11-28 | Principia Biopharma Inc | Tyrosine kinase inhibitors |
| WO2012158795A1 (en) * | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| EP2726077A4 (en) * | 2011-06-28 | 2014-12-10 | Pharmacyclics Inc | METHODS AND COMPOSITIONS FOR INHIBITING BONE RESORPTION |
| KR20140048968A (ko) * | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
| ES2834093T3 (es) | 2011-07-21 | 2021-06-16 | Sumitomo Dainippon Pharma Oncology Inc | Inhibidores de proteína quinasa heterocíclicos |
| TW201325593A (zh) | 2011-10-28 | 2013-07-01 | Celgene Avilomics Res Inc | 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法 |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| TW201336847A (zh) * | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| ES2580530T3 (es) * | 2012-02-23 | 2016-08-24 | Taiho Pharmaceutical Co., Ltd. | Compuesto con anillo fusionado de quinolilpirrolopirimidilo o sal del mismo |
| ES2880109T3 (es) | 2012-03-15 | 2021-11-23 | Celgene Car Llc | Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico |
| CA2866857C (en) | 2012-03-15 | 2021-03-09 | Celgene Avilomics Research, Inc. | Salts of an epidermal growth factor receptor kinase inhibitor |
| ES2681050T3 (es) | 2012-04-11 | 2018-09-11 | Acerta Pharma B.V. | Inhibidores de la tirosina quinasa de Bruton para la movilización hematopoyética |
| WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| CN104662018B (zh) | 2012-04-20 | 2017-10-24 | 阿迪维纳斯治疗有限公司 | 取代的杂双环化合物、组合物及其医疗应用 |
| US9796716B2 (en) * | 2012-05-31 | 2017-10-24 | Pharmascience, Inc. | Selective inhibitors of Tec and Src protein kinase families |
| UA114421C2 (uk) | 2012-06-04 | 2017-06-12 | Фармасайклікс Ллс | Кристалічна форма інгібітору тирозинкінази брутона |
| CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
| PT2892900T (pt) | 2012-09-10 | 2017-11-06 | Principia Biopharma Inc | Compostos de pirazolopirimidina como inibidores de cinase |
| WO2014055934A2 (en) | 2012-10-04 | 2014-04-10 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
| US9828376B2 (en) | 2012-10-04 | 2017-11-28 | University Of Utah Research Foundation | Substituted N-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors |
| MX2015006168A (es) | 2012-11-15 | 2015-08-10 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas. |
| CN103848810A (zh) | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
| US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| KR20150119012A (ko) | 2013-02-08 | 2015-10-23 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Erk 억제제 및 이의 용도 |
| KR20150119401A (ko) | 2013-02-22 | 2015-10-23 | 다이호야쿠힌고교 가부시키가이샤 | 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물 |
| PT2970205T (pt) | 2013-03-14 | 2019-08-26 | Tolero Pharmaceuticals Inc | Inibidores da jak2 e da alk2 e métodos para a sua utilização |
| ES2924193T3 (es) * | 2013-03-15 | 2022-10-05 | Janssen Pharmaceutica Nv | Procesos e intermedios para preparar un medicamento |
| WO2014152114A1 (en) * | 2013-03-15 | 2014-09-25 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as btk inhibitors |
| JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CA2902686C (en) | 2013-04-25 | 2017-01-24 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
| GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
| CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
| TWI649081B (zh) | 2013-08-02 | 2019-02-01 | 製藥公司 | 治療固態腫瘤之方法 |
| US9415050B2 (en) | 2013-08-12 | 2016-08-16 | Pharmacyclics Llc | Methods for the treatment of HER2 amplified cancer |
| HUE034807T2 (en) | 2013-08-22 | 2018-02-28 | Taiho Pharmaceutical Co Ltd | New quinoline-substituted compound |
| KR102339228B1 (ko) | 2013-08-23 | 2021-12-13 | 뉴파마, 인크. | 특정 화학 물질, 조성물, 및 방법 |
| US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
| AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
| MA38961A1 (fr) | 2013-09-30 | 2018-05-31 | Pharmacyclics Llc | Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose |
| WO2015057992A1 (en) | 2013-10-16 | 2015-04-23 | Izumi Raquel | Btk inhibitors for hematopoietic mobilization |
| CN105814035B (zh) * | 2013-12-13 | 2018-02-02 | 豪夫迈·罗氏有限公司 | 布鲁顿氏酪氨酸激酶抑制剂 |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| JP6162904B2 (ja) | 2014-02-03 | 2017-07-12 | カディラ ヘルスケア リミティド | 新規複素環式化合物 |
| EP3107544B1 (en) | 2014-02-21 | 2020-10-07 | Principia Biopharma Inc. | Salts and solid form of a btk inhibitor |
| WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
| US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
| EP3134418A4 (en) | 2014-04-23 | 2018-01-03 | The Research Foundation for The State University of New York | A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith |
| CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| WO2015172713A1 (zh) * | 2014-05-13 | 2015-11-19 | 广东东阳光药业有限公司 | 一种中间体的制备方法 |
| CN104086551B (zh) * | 2014-06-06 | 2016-09-21 | 人福医药集团股份公司 | 化合物及其制备方法和用途 |
| GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
| WO2016000619A1 (en) | 2014-07-03 | 2016-01-07 | Beigene, Ltd. | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics |
| CA2959602A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| BR112017002231A2 (pt) | 2014-08-07 | 2018-07-17 | Pharmacyclics Llc | novas formulações de um inibidor de tirosina cinase de bruton |
| DK3179858T3 (da) | 2014-08-13 | 2019-07-22 | Celgene Car Llc | Forme og sammensætninger af en ERK-inhibitor |
| ES2727952T3 (es) | 2014-10-01 | 2019-10-21 | Ratiopharm Gmbh | Sal de adición de ácido de ibrutinib |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| CA2970723C (en) | 2014-12-18 | 2023-09-05 | Principia Biopharma Inc. | Treatment of pemphigus |
| EP3042903B1 (en) | 2015-01-06 | 2019-08-14 | Impetis Biosciences Ltd. | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| MA41350A (fr) * | 2015-01-14 | 2017-11-21 | Janssen Pharmaceutica Nv | Synthèse d'un inhibiteur de la tyrosine kinase de bruton |
| CN105481862B (zh) * | 2015-01-21 | 2018-08-21 | 中国科学院合肥物质科学研究院 | Flt3激酶的新型抑制剂及其用途 |
| WO2016115869A1 (zh) * | 2015-01-21 | 2016-07-28 | 中国科学院合肥物质科学研究院 | Flt3激酶的新型抑制剂及其用途 |
| CN105859721B (zh) * | 2015-01-22 | 2018-04-17 | 浙江京新药业股份有限公司 | 一种伊布鲁替尼的制备方法 |
| JP6681922B2 (ja) * | 2015-02-12 | 2020-04-15 | 上▲海▼度▲徳▼医▲藥▼科技有限公司 | イブルチニブの製造方法 |
| US10947201B2 (en) | 2015-02-17 | 2021-03-16 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| SG11201707122QA (en) | 2015-03-03 | 2017-09-28 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibtor |
| US10045990B2 (en) | 2015-03-04 | 2018-08-14 | Arizona Board Of Regents On Behalf Of Arizona State University | ERBB4 inhibitors and methods of use thereof |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
| CN106146516B (zh) * | 2015-04-20 | 2019-02-15 | 北京睿创康泰医药研究院有限公司 | 依鲁替尼药物杂质的制备方法 |
| RS62290B1 (sr) * | 2015-06-03 | 2021-09-30 | Principia Biopharma Inc | Inhibitori tirozinske kinaze |
| US9394312B1 (en) * | 2015-06-14 | 2016-07-19 | Mark Quang Nguyen | Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use |
| TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
| EP4116303A1 (en) | 2015-09-16 | 2023-01-11 | Loxo Oncology, Inc. | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer |
| PE20220507A1 (es) * | 2015-12-16 | 2022-04-07 | Loxo Oncology Inc | Compuestos utiles como inhibidores de cinasa |
| CN108473467B (zh) | 2015-12-24 | 2021-08-13 | 武田药品工业株式会社 | 共结晶、其制造方法及含有共结晶的药物 |
| BR112018012106B1 (pt) * | 2016-01-05 | 2023-12-12 | Jiangsu Hengrui Medicine Co., Ltd | Forma cristalina i de (r)-4-amino-1-(1-(but-2-inoil)pirrolidin-3-il)-3-(4- (2,6- difluorofenoxi)fenil)-1h-pirrolo[2,3-d]piridazin-7(6h)-ona, método de preparar a forma cristalina i, composição farmacêutica e uso da forma cristalina i |
| JP7109365B2 (ja) * | 2016-01-19 | 2022-07-29 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｂｔｋ阻害剤を含む製剤／組成物 |
| US10793566B2 (en) | 2016-01-21 | 2020-10-06 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
| MX2018008815A (es) | 2016-01-21 | 2019-03-28 | Zibo Biopolar Changsheng Pharmaceutical Co Ltd | Inhibidores de tirosina quinasa de bruton. |
| CN106995446B (zh) * | 2016-01-22 | 2021-07-02 | 山东新时代药业有限公司 | 布鲁顿酪氨酸激酶抑制剂制备方法 |
| CN115746000A (zh) | 2016-03-11 | 2023-03-07 | 嘉兴和剂药业有限公司 | 用于调节布鲁顿酪氨酸激酶的化合物及方法 |
| WO2017198049A1 (zh) * | 2016-05-16 | 2017-11-23 | 浙江予川医药科技有限公司 | 作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物 |
| EP3478273A1 (en) | 2016-06-29 | 2019-05-08 | Principia Biopharma Inc. | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| CN109843858B (zh) * | 2016-08-15 | 2023-05-05 | 润新生物公司 | 某些化学实体、组合物及方法 |
| AU2017314178B2 (en) * | 2016-08-16 | 2021-11-18 | Beigene Switzerland Gmbh | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| EP4353747A2 (en) | 2016-08-19 | 2024-04-17 | BeiGene Switzerland GmbH | Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer |
| US20190201409A1 (en) | 2016-09-19 | 2019-07-04 | Mei Pharma, Inc. | Combination therapy |
| JOP20190073A1 (ar) | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 |
| JOP20190113A1 (ar) * | 2016-11-18 | 2019-05-15 | Biocad Joint Stock Co | مثبطات بروتون تيروزين كيناز |
| CN110545826A (zh) | 2016-12-03 | 2019-12-06 | 朱诺治疗学股份有限公司 | 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物 |
| WO2018137681A1 (en) | 2017-01-25 | 2018-08-02 | Beigene, Ltd. | Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof |
| CN109311883B (zh) * | 2017-02-09 | 2021-03-19 | 合肥合源药业有限公司 | Flt3激酶抑制剂或其盐的晶型及其制备方法 |
| US11597768B2 (en) | 2017-06-26 | 2023-03-07 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
| CN110997677A (zh) | 2017-08-12 | 2020-04-10 | 百济神州有限公司 | 具有改进的双重选择性的Btk抑制剂 |
| JOP20200044A1 (ar) | 2017-09-01 | 2020-02-26 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي egfr طافر exon 18 و/أو exon 21 |
| TW201922256A (zh) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
| CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
| CN108191871B (zh) * | 2018-01-02 | 2020-02-18 | 成都倍特药业有限公司 | 新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用 |
| MX2020010437A (es) | 2018-04-05 | 2021-01-29 | Sumitomo Pharma Oncology Inc | Inhibidores de axl cinasa y uso de los mismos. |
| CN117838695A (zh) | 2018-04-13 | 2024-04-09 | 住友制药肿瘤公司 | 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂 |
| CA3103995A1 (en) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
| CN109134472B (zh) * | 2018-09-20 | 2020-02-11 | 浙江理工大学 | 一种3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]嘧啶-4-胺的合成工艺 |
| CN110964016B (zh) * | 2018-09-29 | 2021-05-28 | 南京药捷安康生物科技有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
| CN109369654A (zh) * | 2018-11-20 | 2019-02-22 | 山东大学 | 1，3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用 |
| CN111454268B (zh) * | 2019-01-18 | 2023-09-08 | 明慧医药（上海）有限公司 | 作为布鲁顿酪氨酸激酶抑制剂的环状分子 |
| CN113412262A (zh) | 2019-02-12 | 2021-09-17 | 大日本住友制药肿瘤公司 | 包含杂环蛋白激酶抑制剂的制剂 |
| JP2022534650A (ja) * | 2019-05-31 | 2022-08-03 | 海思科医▲薬▼有限公司 | Ｂｔｋ阻害薬環誘導体、その調製方法及びその医薬品適用 |
| CN110606848A (zh) * | 2019-08-27 | 2019-12-24 | 药雅科技(上海)有限公司 | 一种5-氮杂吲哚衍生物Bruton′s酪氨酸激酶抑制剂及其制备方法与用途 |
| CN115038700A (zh) | 2019-11-08 | 2022-09-09 | 内尔维亚诺医疗科学公司 | 偕二取代的杂环化合物及其作为idh抑制剂的用途 |
| IL294560A (en) | 2020-01-20 | 2022-09-01 | Genzyme Corp | Medicinal tyrosine kinase inhibitors for relapsing multiple sclerosis |
| CN113943294A (zh) * | 2020-07-15 | 2022-01-18 | 成都海博为药业有限公司 | 一种作为btk抑制剂的化合物及其制备方法与用途 |
| US20240002387A1 (en) * | 2020-11-25 | 2024-01-04 | Haisco Pharmaceuticals Pte. Ltd. | Method for preparing btk degrading agent |
| CN113004246B (zh) * | 2021-02-22 | 2022-02-01 | 广西医科大学 | 1，3，5-三嗪-2-胺-4，6取代衍生物或其药学上可接受的盐和用途 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2008A (en) * | 1841-03-18 | Gas-lamp eok conducting gas pkom ah elevated buhner to one below it | ||
| US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3993073A (en) | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4069307A (en) | 1970-10-01 | 1978-01-17 | Alza Corporation | Drug-delivery device comprising certain polymeric materials for controlled release of drug |
| US3731683A (en) | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
| US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
| US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
| BE795384A (fr) | 1972-02-14 | 1973-08-13 | Ici Ltd | Pansements |
| US3921636A (en) | 1973-01-15 | 1975-11-25 | Alza Corp | Novel drug delivery device |
| US3993072A (en) | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
| US4151273A (en) | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
| US3972995A (en) | 1975-04-14 | 1976-08-03 | American Home Products Corporation | Dosage form |
| US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4031894A (en) | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
| US4060084A (en) | 1976-09-07 | 1977-11-29 | Alza Corporation | Method and therapeutic system for providing chemotherapy transdermally |
| US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
| JPS5562012A (en) | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
| US4230105A (en) | 1978-11-13 | 1980-10-28 | Merck & Co., Inc. | Transdermal delivery of drugs |
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| US4291015A (en) | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
| EP0230654B1 (en) | 1985-12-28 | 1992-03-18 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| US5633009A (en) | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
| AU1537292A (en) | 1991-04-16 | 1992-11-17 | Nippon Shinyaku Co. Ltd. | Method of manufacturing solid dispersion |
| EP0613373B1 (en) | 1991-11-22 | 2000-08-02 | THE PROCTER & GAMBLE PHARMACEUTICALS, INC. | Risedronate delayed-release compositions |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
| US5281420A (en) | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| AU4198793A (en) | 1992-07-24 | 1994-01-27 | Takeda Chemical Industries Ltd. | Microparticle preparation and production thereof |
| US5700485A (en) | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
| DE69332291T2 (de) | 1992-10-16 | 2003-07-31 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung von wachsmatrizes |
| US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| US5665378A (en) | 1994-09-30 | 1997-09-09 | Davis; Roosevelt | Transdermal therapeutic formulation |
| US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
| SE9502244D0 (sv) | 1995-06-20 | 1995-06-20 | Bioglan Ab | A composition and a process for the preparation thereof |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US6923983B2 (en) | 1996-02-19 | 2005-08-02 | Acrux Dds Pty Ltd | Transdermal delivery of hormones |
| US6929801B2 (en) | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| ID24653A (id) * | 1997-03-19 | 2000-07-27 | Basf Ag | Zat-zat terapi |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| US5869090A (en) | 1998-01-20 | 1999-02-09 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
| US6946144B1 (en) | 1998-07-08 | 2005-09-20 | Oryxe | Transdermal delivery system |
| JP2002526500A (ja) * | 1998-09-18 | 2002-08-20 | ビーエーエスエフ アクチェンゲゼルシャフト | プロテインキナーゼ阻害剤としてのピロロピリミジン |
| ES2307482T3 (es) | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| SK3812002A3 (en) | 1999-09-17 | 2003-09-11 | Abbott Gmbh & Co Kg | Pyrazolopyrimidines as therapeutic agents |
| AU2001262960A1 (en) | 2000-04-28 | 2001-11-12 | Zengen, Inc. | New antibodies to biological membranes |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| US6960563B2 (en) | 2001-08-31 | 2005-11-01 | Morton Grove Pharmaceuticals, Inc. | Spontaneous emulsions containing cyclosporine |
| BRPI0418031A (pt) * | 2003-12-22 | 2007-04-17 | Gilead Sciences Inc | inibidores de quinase fosfonato-substituìdos |
| AU2004308974A1 (en) * | 2003-12-22 | 2005-07-14 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
| JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
| JP2008520744A (ja) * | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
| NZ571182A (en) * | 2006-04-04 | 2010-09-30 | Univ California | Pyrazolo[3,4-d]pyrimidines |
| BRPI0622054B8 (pt) * | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| MX2009010284A (es) * | 2007-03-28 | 2010-01-29 | Pharmacyclics Inc | Inhibidores de la tirosina-cinasa de bruton. |
| US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| EP2488028B1 (en) | 2009-10-14 | 2020-08-19 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
-
2009
- 2009-10-16 US US12/581,044 patent/US7718662B1/en active Active
- 2009-10-16 US US12/581,062 patent/US7741330B1/en active Active
-
2010
- 2010-10-12 EA EA201270553A patent/EA021715B1/ru unknown
- 2010-10-12 US US12/903,101 patent/US9012463B2/en active Active
- 2010-10-12 KR KR20127011767A patent/KR20120097376A/ko not_active Application Discontinuation
- 2010-10-12 IN IN3012DEN2012 patent/IN2012DN03012A/en unknown
- 2010-10-12 JP JP2012534294A patent/JP5717109B2/ja active Active
- 2010-10-12 EP EP10823966A patent/EP2393816A4/en not_active Withdrawn
- 2010-10-12 EP EP13166272.8A patent/EP2650294B1/en active Active
- 2010-10-12 MX MX2012004258A patent/MX2012004258A/es active IP Right Grant
- 2010-10-12 ES ES13166272.8T patent/ES2590905T3/es active Active
- 2010-10-12 BR BR112012008624A patent/BR112012008624A2/pt not_active IP Right Cessation
- 2010-10-12 WO PCT/US2010/052377 patent/WO2011046964A2/en active Application Filing
- 2010-10-12 SG SG10201506776RA patent/SG10201506776RA/en unknown
- 2010-10-12 AU AU2010306921A patent/AU2010306921C1/en active Active
- 2010-10-12 CA CA2776543A patent/CA2776543A1/en not_active Abandoned
- 2010-10-12 NZ NZ59939610A patent/NZ599396A/en unknown
- 2010-10-12 CN CN201080056387.2A patent/CN102656173B/zh active Active
-
2012
- 2012-04-05 IL IL219076A patent/IL219076A/en active IP Right Grant
- 2012-04-09 CO CO12057551A patent/CO6531429A2/es active IP Right Grant
- 2012-04-10 ZA ZA2012/02552A patent/ZA201202552B/en unknown
- 2012-04-11 CL CL2012000917A patent/CL2012000917A1/es unknown
- 2012-05-11 CR CR20120244A patent/CR20120244A/es unknown
-
2013
- 2013-11-20 US US14/085,722 patent/US20140080844A1/en not_active Abandoned
-
2015
- 2015-03-10 JP JP2015047643A patent/JP2015134802A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266741A (en) | Broton tyrosine kinase inhibitors | |
| ZA201301679B (en) | Inhibitors of bruton's tyrosine kinase | |
| ZA201202552B (en) | Inhibitors of bruton's tyrosine kinase | |
| ZA201300705B (en) | Inhibitors of bruton's tyrosine kinase | |
| EP2473049A4 (en) | BRUTON TYROSINE KINASE INHIBITORS | |
| IL288009A (en) | Use of proton tyrosine kinase inhibitors | |
| HK1254663A1 (zh) | 用於實體腫瘤的治療的布魯頓酪氨酸激酶的抑制劑 | |
| ZA201400012B (en) | Inhibitors of bruton's tyrosine kinase | |
| ZA201308397B (en) | Inhibitors of bruton's tyrosine kinase | |
| ZA201400739B (en) | Inhibitors of bruton's tyrosine kinase | |
| ZA201209381B (en) | The use of inhibitors of bruton's tyrosine kinase (btk) | |
| EP2925740A4 (en) | INHIBITORS OF BRUTON TYROSINE KINASE | |
| IL238571A0 (en) | Broton tyrosine kinase inhibitors, preparations containing them and their uses | |
| EP2858500A4 (en) | INHIBITORS OF BRUTON TYROSINE KINASE | |
| EP2488025A4 (en) | SEPIAPTERIC INTREDUCTASE INHIBITION FOR PAIN TREATMENT | |
| EP2515657A4 (en) | TYROSINE KINASE INHIBITORS | |
| EP2384118A4 (en) | SPHINGOGUANIDINE AND ITS USE AS AN INHIBITOR OF SPHINGOSINKINASE | |
| PL2237782T3 (pl) | Zastosowanie tetrahydropirymidyn | |
| AU2013276959B2 (en) | Inhibitors of Bruton's tyrosine kinase |